Log In
Print
BCIQ
Print
Print this Print this
 

SCY-078 (formerly MK-3118)

  Manage Alerts
Collapse Summary General Information
Company Scynexis Inc.
DescriptionSemi-synthetic derivative of enfumafungin, a beta 1,3-D-glucan synthase inhibitor
Molecular Target Beta 1,3-D-glucan synthase
Mechanism of ActionAntioxidant
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationFungal infection
Indication DetailsTreat aspergillosis; Treat candidiasis infections
Regulatory Designation U.S. - Fast Track (Treat aspergillosis);
U.S. - Fast Track (Treat candidiasis infections);
U.S. - Qualified Infectious Disease Program (Treat candidiasis infections);
U.S. - Qualified Infectious Disease Program (Treat aspergillosis)
Partner R-Pharm CJSC

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today